<DOC>
	<DOCNO>NCT01491204</DOCNO>
	<brief_summary>The main objective study determine maximum tolerate dose ( MTD ) Oral Paclitaxel . Eligible subject study patient histologically cytologically confirm malignant solid tumor refractory standard therapy . Administration Schedule : 1 cycle Oraxol® ( paclitaxel+HM30181A ) medication 28 day Oraxol® administrate total 3 time week ( day 1 , 8 , 15 ) . The next cycle start day 29 . Methods Administration : HM30181A tablet administer 1hour prior medication paclitaxel</brief_summary>
	<brief_title>Clinical Trial Determine Maximum Tolerated Dose Assess Safety Pharmacokinetic Profile Oral Paclitaxel Patients With Advanced Solid Cancer</brief_title>
	<detailed_description>Besides main objective , 3 objective follow . To determine dose-limiting toxicity ( DLT ) Of Oraxol . To characterize pharmacokinetics HM30181A ( pgp inhibitor ) , paclitaxel metabolite follow oral administration Oraxol . To evaluate anticancer activity Oraxol .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Patients must histologically cytologically diagnose advanced solid cancer . 2 . Patients progressive disease spite standard anticancer therapy expect benefit prolong survival exist anticancer therapy 3 . Patients receive chemotherapy , radiation therapy , surgery must pass least 4weeks since final treatment must fully recover toxicity Patients treat Nitrosoureas Mitomycin C must wait 6 week become eligible . 4 . ECOG performance status ≤ 2 5 . Life expectancy ≥ 12 week 6 . Patients proper bone marrow , kidney , liver function patient remarkable dysfunction heart lung : WBC≥4000/mm3 ; Platelet ≥100,000/mm3 ; Hemoglobin≥9.0g/dL ; ANC≥ 1,500 /mm3 ; Creatinine ≤ 1.5mg/dL ; AST/ALT/ALP ≤ 3 X upper limit normal ; Total bilirubin ≤2.0mg/dL *AST/ALT/ALP ≤ 3 X upper limit normal &lt; 5 liver bone metastasis present 1 . Patients blood tumor ( ex , leukemia ) , uncontrolled infectious disease , neurologic disorder , metastasis CNS ileus ( patient require nonoral administration antibiotic treat active bacterial infection eligible , patient participate trial complete eradication control infection ) 2 . Patients receive bone marrow transplant receive bone marrow transplant . 3 . Patients medical history atrial ventricular arrhythmia congestive heart failure receive medical treatment myocardial infarction within 6 month . 4 . Pregnant lactate childbearing potential without use adequate contraception ( case men , appropriate contraception require ) . 5 . Patients PGP inhibitor Cyclosporine Verapamil prohibit . : Such patient may qualify twoweek washout period .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>